Atara Biotherapeutics, Inc. (ATRA)
Stock Price:
$12.73 USD
0.18 (1.43%)
Updated Aug 7, 2020 4:00 PM EDT - Market closed
Key Info
| Market Cap |
911.28M |
| Revenue (ttm) |
n/a |
| Net Income (ttm) |
-301.36M |
| Shares Out |
74.31M |
| EPS (ttm) |
-4.98 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Aug 7, 2020 |
| Last Price |
$12.73 |
| Previous Close |
$12.55 |
| Change ($) |
0.18 |
| Change (%) |
1.43% |
| Day's Open |
12.50 |
| Day's Range |
12.35 - 13.04 |
| Day's Volume |
492,785 |
| 52-Week Range |
4.52 - 19.36 |
More Stats
| Market Cap |
911.28M |
| Enterprise Value |
576.79M |
| Earnings Date (est) |
Nov 5, 2020 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
74.31M |
| Float |
54.50M |
| EPS (basic) |
-5 |
| EPS (diluted) |
-4.98 |
| FCF / Share |
-3.56 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
13.56M |
| Short Ratio |
8.58 |
| Short % of Float |
23.20% |
| Beta |
2.22 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
n/a |
| PB Ratio |
3.95 |
| Revenue |
n/a |
| Operating Income |
-304.90M |
| Net Income |
-301.36M |
| Free Cash Flow |
-242.06M |
| Net Cash |
334.49M |
| Net Cash / Share |
4.67 |
| Gross Margin |
n/a |
| Operating Margin |
n/a |
| Profit Margin |
n/a |
| FCF Margin |
n/a |
| ROA |
-54.27% |
| ROE |
-98.26% |
| ROIC |
-115.20% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (12)
| Buy |
9 |
| Overweight |
0 |
| Hold |
2 |
| Underweight |
0 |
| Sell |
1 |
Price Target
$27.56*
(116.50% upside)
Low
8.00
Current: $12.73
High
70.00
Target: 27.56
*Average 12-month price target from 9 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 |
|---|
| Revenue | - | - | - | - | - | - | - |
| Operating Income | -296 | -237 | -122 | -81.24 | -58.45 | -28.16 | -8.62 |
| Net Income | -291 | -231 | -119 | -79.05 | -57.22 | -28.01 | -8.77 |
| Shares Outstanding | 51.31 | 43.81 | 29.86 | 28.73 | 25.58 | 4.99 | 0.97 |
| Earnings Per Share | -5.67 | -5.27 | -4.00 | -2.75 | -2.24 | -5.62 | -9.08 |
| Operating Cash Flow | -236 | -180 | -87.50 | -60.03 | -37.16 | -16.63 | -5.97 |
| Capital Expenditures | -5.57 | -35.93 | -20.23 | -3.02 | -0.29 | -0.05 | - |
| Free Cash Flow | -241 | -216 | -108 | -63.05 | -37.45 | -16.67 | -5.97 |
| Cash & Equivalents | 259 | 310 | 166 | 256 | 321 | 104 | 51.62 |
| Total Debt | 14.14 | - | - | - | - | - | - |
| Net Cash / Debt | 245 | 310 | 166 | 256 | 321 | 104 | 51.62 |
| Assets | 343 | 392 | 218 | 264 | 325 | 106 | 51.83 |
| Liabilities | 52.16 | 52.98 | 39.92 | 10.18 | 9.88 | 2.94 | 1.75 |
| Book Value | 291 | 339 | 178 | 254 | 315 | 103 | -11.02 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Atara Biotherapeutics, Inc. |
| Country |
United States |
| Employees |
409 |
| CEO |
Pascal Touchon |
Stock Information
| Ticker Symbol |
ATRA |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: ATRA |
| IPO Date |
October 16, 2014 |
Description
Atara Biotherapeutics, Inc., an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase III clinical trials for the treatment of rituximab-refractory epstein-barr virus (EBV) associated post-transplant lymphoproliferative disorder, as well as other EBV associated hematologic and solid tumors, including nasopharyngeal carcinoma. The company is also developing next-generation CAR T immunotherapies for patients with hematologic malignancies and solid tumors, and autoimmune and viral diseases, including ATA2271 for mesothelin; ATA2321 for acute myeloid leukemia; and ATA2431 and ATA3219 for B-cell lymphomas, as well as ATA188 and ATA190 that are in Phase I clinical trials for the treatment of multiple sclerosis. In addition, it is developing ATA621 against the BK and JC viruses; ATA368 for patients with human papillomavirus and associated cancers; ATA520 to treat Wilms tumor 1; and ATA230 against cytomegalovirus and related diseases. The company has a license agreement with Memorial Sloan Kettering Cancer Center; license, and research and development collaboration agreement with QIMR Berghofer Medical Research Institute; and strategic collaboration with H. Lee Moffitt Cancer Center. Atara Biotherapeutics, Inc. was founded in 2012 and is headquartered in South San Francisco, California.